ATE399548T1 - Vorbeugung der entwicklung von dyskinesie - Google Patents

Vorbeugung der entwicklung von dyskinesie

Info

Publication number
ATE399548T1
ATE399548T1 AT01996370T AT01996370T ATE399548T1 AT E399548 T1 ATE399548 T1 AT E399548T1 AT 01996370 T AT01996370 T AT 01996370T AT 01996370 T AT01996370 T AT 01996370T AT E399548 T1 ATE399548 T1 AT E399548T1
Authority
AT
Austria
Prior art keywords
development
dyskinesia
preventing
alfa2
prevention
Prior art date
Application number
AT01996370T
Other languages
English (en)
Inventor
Antti Haapalinna
Juuso Juhila
Jouni Sirvioe
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Application granted granted Critical
Publication of ATE399548T1 publication Critical patent/ATE399548T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01996370T 2000-11-14 2001-11-13 Vorbeugung der entwicklung von dyskinesie ATE399548T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24800400P 2000-11-14 2000-11-14

Publications (1)

Publication Number Publication Date
ATE399548T1 true ATE399548T1 (de) 2008-07-15

Family

ID=22937245

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01996370T ATE399548T1 (de) 2000-11-14 2001-11-13 Vorbeugung der entwicklung von dyskinesie

Country Status (8)

Country Link
US (2) US20040039041A1 (de)
EP (1) EP1333828B1 (de)
JP (1) JP2004513917A (de)
AT (1) ATE399548T1 (de)
AU (1) AU2002223703A1 (de)
CA (1) CA2428603C (de)
DE (1) DE60134659D1 (de)
WO (1) WO2002039991A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110826A1 (en) * 2001-09-28 2004-06-10 Noriaki Uesaka Receptor Antagonists
FI20022007A0 (fi) 2002-11-08 2002-11-08 Juvantia Pharma Ltd Oy Oromukosaalinen valmiste ja menetelmä sen valmistamiseksi
JPWO2005066357A1 (ja) * 2004-01-05 2007-12-20 三菱ウェルファーマ株式会社 精神疾患関連分子のスクリーニング方法
JPWO2016104367A1 (ja) * 2014-12-22 2017-09-28 株式会社Ｌｔｔバイオファーマ 機能性ディスペプシア治療薬

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492907A (en) * 1992-12-09 1996-02-20 The United States Of America As Represented By The Department Of Health & Human Services Antipsychotic composition and method of treatment
FR2706303B1 (fr) * 1993-06-18 1995-09-08 Pf Medicament Utilisation de l'Efaroxan et de ses dérivés pour la préparation d'un médicament destiné au traitement de la maladie de Parkinson.
FR2759291A1 (fr) * 1997-02-13 1998-08-14 Pf Medicament Produit contenant de l'idazoxan et de la 1-dopa comme preparation pharmaceutique combinee utilise pour la maladie de parkinson
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine

Also Published As

Publication number Publication date
AU2002223703A1 (en) 2002-05-27
CA2428603C (en) 2010-06-22
DE60134659D1 (de) 2008-08-14
US20020115703A1 (en) 2002-08-22
EP1333828B1 (de) 2008-07-02
CA2428603A1 (en) 2002-05-23
WO2002039991A2 (en) 2002-05-23
WO2002039991A3 (en) 2002-08-29
JP2004513917A (ja) 2004-05-13
EP1333828A2 (de) 2003-08-13
US20040039041A1 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
PL361404A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
BG66085B1 (bg) Фенилаланинови производни
DOP2001000151A (es) Derivados de imidazopirimidina y derivados de triazolopimidina.
DK1663229T3 (da) Farmaceutiske kombinationer af hydrocodon og naltrexon
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
PT1109812E (pt) Pirrolobenzodiazepinas
DE69942306D1 (de) Abkömmlinge von glp-1 analogen
HN2002000028A (es) Pirimidinas inhibidoras de metaloproteinasas
IS6069A (is) N-cýanómetýlamíð sem próteasalatar
DE122011100062I1 (de) Phosphonatderivate eines glykopeptides.
BR0110998A (pt) Derivados de fenilglicina
DE69830504D1 (de) Antithrombotische mitteln
ATE283253T1 (de) Substituierte aminopropoxyarylderivate als lxr agonisten
BR0313420A (pt) Quinolonas microbicidas, suas composições e usos
NO20052884L (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
DE60008524D1 (de) Furanonderivate als inhibitoren von cathepsin s
PE20011085A1 (es) Compuestos isoxazolquinolin o imidazolquinolin como inhibidores de la proteina resistente a multifarmacos
ATE399011T1 (de) Substituierte diketopiperazine als oxytocin- antagonisten
SE9901077D0 (sv) Novel use
EA200401183A1 (ru) Применение ингибиторов il-18 в качестве диагностического маркера
BR0314844A (pt) Novo composto
BR0314843A (pt) Novo composto
TNSN06138A1 (fr) Inhibitors of the mutant form of kit
BR9809848A (pt) Composição
ATE308540T1 (de) Antithrombosemittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties